Xeomin^®, a Commercial Formulation of Botulinum Neurotoxin Type A, Promotes Regeneration in a Preclinical Model of Spinal Cord Injury.

At D3, ΔBMS was calculated with respect to baseline value of BMS = 9 (normal movement of the hindlimbs) and the days from SCI, which in our experimental protocol is equal to 3, by using the Equation (1): ΔBMS at D3 = ((BMS value at D3 − 9)/3) (1) while at Dx (x = 7, 10, 14, 21, 28, 35), ΔBMS was calculated with respect to BMS value at D3 and the days from D3, by using the Equation (2): ΔBMS at Dx = ((BMS value at Dx − BMS value at D3)/days from D3) (2) Although an increasing trend was observed, the mean ΔBMS of saline- or Xeomin ® -treated SCI mice was not different from D3 to D21.

also in 63,971 other papers